<?xml version="1.0" encoding="UTF-8"?>
<p id="Par46">COVID-19 emerged in late 2019 and was soon found to be caused by SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR11">11</xref>, 
 <xref ref-type="bibr" rid="CR23">23</xref>, 
 <xref ref-type="bibr" rid="CR33">33</xref>]. In early 2020, COVID-19 illness became a pandemic, prompting intensive research efforts toward developing vaccines [
 <xref ref-type="bibr" rid="CR33">33</xref>, 
 <xref ref-type="bibr" rid="CR34">34</xref>]. Several organizations published viral genome sequences to promote the development of safe and efficacious vaccines against SARS-CoV-2 [
 <xref ref-type="bibr" rid="CR33">33</xref>â€“
 <xref ref-type="bibr" rid="CR37">37</xref>]. According to the WHO International Clinical Trials Registry Platform, by March 2020, about 100 academic institutions and organizations were actively working worldwide, with 536 clinical trials being conducted [
 <xref ref-type="bibr" rid="CR22">22</xref>, 
 <xref ref-type="bibr" rid="CR38">38</xref>, 
 <xref ref-type="bibr" rid="CR39">39</xref>]. By March 2020, many clinical investigations involving co-administration of multiple antiviral drugs already registered for use against other diseases had been initiated [
 <xref ref-type="bibr" rid="CR22">22</xref>, 
 <xref ref-type="bibr" rid="CR23">23</xref>].
</p>
